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Abstract 
Provoked vestibulodynia (PVD) is a highly prevalent and debilitating condition yet its 
management relies mainly on non-empirically validated interventions. Among the many causes 
of PVD, there is growing evidence that pelvic floor muscle (PFM) dysfunctions play an important 
role in its pathophysiology. Multimodal physiotherapy, which addresses these dysfunctions, is 
judged by experts to be highly effective and is recommended as a first-line treatment. However, 
the effectiveness of this promising intervention has been evaluated through only two small 
uncontrolled trials. The proposed bi-center, single-blind, parallel group, randomized controlled 
trial (RCT) aims to evaluate the efficacy of multimodal physiotherapy and compare it to a 
frequently used first-line treatment, topical overnight application of lidocaine, in women with 
PVD. A total of 212 women diagnosed with PVD according to a standardized protocol were 
eligible for the study and were randomly assigned to either multimodal physiotherapy or 
lidocaine treatment for 10 weeks. The primary outcome measure is pain during intercourse 
(assessed with a numerical rating scale). Secondary measures include sexual function, pain 
quality, psychological factors (including pain catastrophizing, anxiety, depression and fear of 
pain), PFM morphology and function, and patients' global impression of change. Assessments 
are made at baseline, post-treatment and at the 6-month follow-up. This manuscript presents 
and discusses the rationale, design and methodology of the first RCT investigating physiotherapy 
in comparison to a commonly prescribed first-line treatment, overnight topical lidocaine, for 
women with PVD. 
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1. Introduction 
Vulvodynia, a highly neglected chronic pain condition, has a 7–8% prevalence [1]. Considered as 
the leading cause of pre-menopausal vulvodynia, provoked vestibulodynia (PVD) is characterized 
by an acute pain at the entry of the vagina during application of pressure or attempted vaginal 
penetration [2]. PVD is reported to disrupt personal lives, severely affect sexual function and 
negatively impact quality of life [3] and [4]. It is also related to relationship problems and 
psychological distress [5]. Poorly understood, often misdiagnosed or ignored, such pain leads to 
a high personal cost for patients and substantial financial cost for society. Women multiply their 
medical visits hoping to find relief and rely mainly on non-evidence-based, ineffective 
interventions [6]. 
The exact etiology of PVD remains unclear. Proposed biomedical factors include vaginal 
infections [7], genetic or immune factors [8], hormonal factors [9], or the proliferation of 
nociceptors and sensitization [10]. Pelvic floor muscle (PFM) dysfunctions may also play an 
important role [11], [12] and [13]. It has been reported that women with PVD have heightened 
PFM tone as well as inferior PFM strength, coordination and endurance compared to 
asymptomatic women [11], [12] and [13]. Targeting these dysfunctions, multimodal 
physiotherapy treatment includes education, biofeedback, manual and insertion techniques 
[14]. This intervention is judged highly effective by vulvodynia specialists [15] and is listed as a 
first-line treatment for vulvodynia in clinical guidelines [16] and [17]. Individual physiotherapy 
modalities have been shown to reduce pain significantly in women with PVD [18], [19] and [20]. 
A randomized controlled trial (RCT) showed a 35% pain reduction during intercourse following 
PFM biofeedback [18]. Manual therapy and auto-insertion techniques also appear to reduce 
pain [19] and [20]. However, it should be emphasized that these isolated modalities do not 
realistically represent physiotherapy in a clinical setting as described by Hartmann et al. [14] and 
may yield only partial efficacy compared to a multimodal physiotherapy. To date, the efficacy of 
multimodal physiotherapy has not been evaluated in a RCT. Only three case reports in women 
with dyspareunia [21], [22] and [23] and two small uncontrolled studies [24] and [25] have 
investigated the effectiveness of combined treatment. One retrospective study involving 35 
women with PVD and one prospective uncontrolled trial in 13 women showed an overall 
reduction of pain in 71–77% of women, which exceeds the reported effectiveness of the 
modalities taken separately. Improvements in sexual function and psychological variables are 
also reported [24] and [25]. It is therefore important and timely to evaluate the efficacy of the 
promising multimodal physiotherapy treatment, reflecting current clinical practice, in a RCT 
design. 
Recommended as a first-line treatment in clinical guidelines, topical lidocaine was found to be 
one of the most commonly prescribed treatments for vulvodynia [15], [16] and [17]. The 
hypothesized mechanism of action is that repeated application of this anesthetic could act on 
nociceptor proliferation and sensitization [10]. Reducing their hyperexcitability is presumed to 
yield long-lasting pain reduction [10] and [26]. In a prospective uncontrolled study, Zolnoun et 
al. [26] showed that overnight use of 5% lidocaine ointment applied for eight weeks significantly 
reduced pain and improved sexual function in 59% of participants with PVD. Other studies using 
lidocaine showed improvement in pain and sexual function. However, when comparing 
lidocaine to other treatments, its efficacy was found nonsignificantly different than biofeedback 
in the study of Danielsson et al. [27] and desipramine and/or placebo in the study of Foster et al. 
[28]. The latter's posology and technique of application differed from those of Zolnoun et al. 
[26], which may explain the lower efficacy. In fact, Danielsson et al. [27] instructed women to 
apply lidocaine 2% and 5% five to seven times per day while Foster et al. [28] recommended 
four–five daily applications of lidocaine 2% or 5% diluted in hydrating cream. Overnight 
lidocaine 5% may represent a better treatment option but its efficacy has never been 
investigated using a rigorous RCT design. 
We designed a bi-center RCT to gather convincing evidence about a recommended intervention 
(multimodal physiotherapy) and compare it to another frequently used first-line intervention 
(overnight lidocaine). This paper discusses the rationale, design and methodology as well as 
challenges encountered during study implementation. 
2. Methods 
2.1. Design overview 
This study consists of a single-blind, parallel-group RCT conducted at two Canadian university 
hospital centers. The overall design is shown in Fig. 1. The primary aim is to compare the efficacy 
of multimodal PFM physiotherapy to overnight topical lidocaine for reducing pain during sexual 
intercourse in women with PVD. Considering the reported effectiveness of the two treatments 
[24], [25] and [26] and the opinion of experts, the main hypothesis is that, in comparison to 
lidocaine, women having physiotherapy will show a greater reduction of pain (post-treatment 
and at 6-month follow-up compared to baseline assessment). Secondary aims include 
comparing the effects of the two treatments on: 1) pain quality (affective, sensory and 
evaluative components); 2) sexual function; 3) psychological variables (catastrophizing, anxiety, 
depression, fear of pain); 4) PFM morphology and function and 5) patients' global impression of 
change. 
 
Fig. 1.  Study design flow diagram. 
2.2. Participants 
A total of 212 nulliparous women with PVD, 18 to 45 years old, were recruited for this study. To 
be included, women had to report pain in the vestibule area at an average intensity of 5 or more 
on the Numerical Rating Scale (NRS) during penetration, which is indicative of moderate to 
severe pain [29]. Both primary (i.e. pain appeared at the first sexual intercourse) and secondary 
(i.e. pain occurred after successful unpainful intercourse) subtypes were included in the study. 
In order to confirm the PVD diagnosis, all women underwent a medical history interview and a 
physical examination including a standardized pelvic examination performed by a gynecologist 
of our team [18]. This evaluation followed the diagnostic criteria defined by Friedrich [2] and 
more recently modified by Bergeron et al. [30]: 1) pain in the vestibule following touch or an 
attempted vaginal penetration; 2) acute pain during the cotton-swab test which consists in 
applying pressure following a random order to the vulvar vestibule. The inter-rater reliability of 
this diagnostic method has been demonstrated [30]. Vulvar pain occurring in the absence of an 
underlying recognizable disease and provoked spontaneously as a result of physical contact can 
be classified as PVD [31]. Therefore, our assessment procedure aimed to rule out any other 
specific neuropathology, atrophic vaginitis, dermatoses such as lichen sclerosus, or pathogens 
such as culture- or smear-proven Candida species, Gardnerella, Trichomonas, herpes simplex, 
gonorrhea and chlamydia. More details about the inclusion and exclusion criteria are presented 
in Table 1. 
Table 1. 
Inclusion and exclusion criteria. 
Inclusion criteria 
– 
Aged 18 to 45 years; 
– 
experience moderate to severe pain in at least 90% of attempted sexual 
intercourse with an average intensity of 5/10 on a numeric rating scale of pain 
intensity; 
– 
pain limited to the vestibule during vaginal intercourse and other activities 
exerting pressure (tampon insertion, tight jeans or pants, cycling, horseback 
riding); 
– 
presence of PVD for at least 6 months and diagnosed according to the 
standardized gynecological examination protocol by one of the team 
gynecologists; and 
– 
have a stable sexual partner (sexual activity should include some attempted 
vaginal penetrations in order to evaluate pain intensity). 
Exclusion criteria 
– 
Pelvic pathology associated with a lower genital pain problem (e.g. deep 
dyspareunia) and constant, spontaneous vulvar pain; 
– 
vaginismus (as defined by Diagnostic and Statistical Manual of Mental Disorders 
IV [32]); 
– 
current or previous pregnancy that lasted more than 18 weeks; 
– 
urogynecological conditions (incontinence, pelvic organ prolapse > 1 stage at the 
pelvic organ prolapse quantification [33]); 
– 
active urinary or vaginal infection (or earlier in last 3 months); 
– 
use of medication that can affect pain perception (analgesics, opiates, 
antiepileptic, muscle relaxant); 
– 




major psychological conditions (i.e. depressive symptoms, anxiety) that could 
present a risk for patient safety; 
– 
refusal to refrain from treatments until the 6-month follow-up assessment; 
– 
previously received physiotherapy treatment or overnight use of lidocaine; and 
– 
any coexisting significant medical condition likely to interfere with study 
procedures (e.g. cardiovascular, hematological, central nervous system, 
pulmonary, renal). 
 
2.3. Baseline assessment 
Interested women were invited to contact the research coordinator for a detailed explanation of 
the study followed by a pre-screening of the eligibility criteria. Participants then took part in a 
medical examination with a gynecologist of our team to confirm the diagnosis of PVD. Women 
were then convened to the first evaluation performed by a trained physiotherapist. After signing 
the informed consent, the women underwent a standardized examination: 1) a structured 
interview for gathering socio-demographic information, pain, medical and gynecological history; 
2) validated questionnaires for evaluating pain, sexual function and psychological variables and 
3) physical examination (including PFM morphometry and function). An assessment schedule is 















(6 months after 
treatment) 
Contact information X  X update X update 
Informed consent X    
Structured interview 
(socio-demographic 
information, pain and 
gynecological 
history) 
X  X update X update 
Questionnaires X  X X 
Physical 
examination: 
X  X X 
 –PFM morphology 
(transperineal 
ultrasound) 
    
 –PFM function 
(dynamometry) 








 X   
PFM: Pelvic floor muscles. 
 
2.4. Randomization and blinding 
Eligible participants were assigned with equal probability to one of the two treatment groups. 
Participant randomization was stratified by center, using random permuted blocks of 4 and 6 
using a list computer-generated managed by an independent individual. Investigators, data 
analysts, gynecologists and physiotherapists in charge of the outcome evaluations remain 
blinded to the trial group allocation. The treatment was explained by the research coordinator 
at each site after the baseline evaluation and patients were reminded not to reveal their 
treatment in the initial consent form as well as at the beginning of each evaluation. 
2.5. Post-treatment and follow-up assessments 
Post-treatment evaluation occurs two weeks after treatment as well as at 6-months follow-up, 
when the same procedures as in the baseline evaluation are repeated. Further, the participants 
are asked to rate the perceived improvement and to report any adverse effects related to 
treatment. 
2.6. Outcomes 
Primary and secondary outcomes are presented detailed in Table 3. The primary-outcome 
measure is the NRS, which is used to quantify pain during intercourse. The participant is asked 
to evaluate the average intensity of pain on an 11-point scale from 0 (no pain) to 10 (most 
intense pain). This scale, highly recommended by the Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials (IMMPACT) [34], is widely used in RCTs for chronic pain 
conditions as well as for women with PVD and has shown good validity, reliability and 




PFM: Pelvic floor muscles. 
a NRS: Numerical Rating Scale. 
b MPQ: McGill–Melzack Pain Questionnaire. 
c FSFI: Female Sexual Function Index. 
d IEMSS: Interpersonal Exchange Model of Sexual Satisfaction Questionnaire. 
e FSDS: Female Sexual Distress Scale. 
f PCS-CF: Pain Catastrophizing Scale. 
g STAI: State and Trait Anxiety Inventory. 
h BDI-II: Beck Depression Inventory. 
i PASS-20: Pain Anxiety Symptoms Scale. 
j PGIC: Patient's Global Impression of Change. 
Primary outcome measure 
Pain intensity (NRS)
a
[34] Average pain intensity reported during sexual 
intercourse 
Secondary outcome measures 
MPQ
b
[35] Quality of pain: sensory, affective and evaluative 
components of pain 
FSFI
c
[36] Sexual functioning: desire and arousal, lubrication, 
orgasm, satisfaction and pain/discomfort 
IEMSS
d
[37] Sexual satisfaction 
FSDS
e
[38] Sexually related personal distress 
PCS-CF
f
[39] Pain catastrophizing: rumination, magnification and 
helplessness towards pain 
STAI
g




[41] Depressive symptoms 
PASS-20
i
[42] and [55] Fear of pain 
PGIC
j
[43] Patient's perceived changes after treatment 
4D ultrasound [12] PFM morphology 
Dynamometry [47], [48], [49], [50],[51], [52], [53] and [54] PFM function 
Several secondary outcomes are assessed in this study, in line with the IMMPACT consensus 
recommending a multi-facetted evaluation of pain, and also an evaluation of the impact of pain 
on function [34]. For each outcome we have selected measure instruments that have excellent 
validity, reliability and responsiveness to change. The McGill–Melzack pain questionnaire (MPQ) 
assesses the quality of pain by investigating its sensory, affective and evaluative components 
[35]. 
The Female Sexual Function Index (FSFI) is a multidimensional measure of sexual function 
evaluating desire, arousal, lubrication, orgasm, satisfaction and pain [36]. The Interpersonal 
Exchange Model of Sexual Satisfaction Questionnaire (IEMSS) is used to investigate sexual 
satisfaction [37]. Lastly, the Female Sexual Distress Scale (FSDS) 12-item questionnaire is 
employed to measure sexually-related personal distress [38]. 
Several psychological variables are also evaluated: (1) the Pain Catastrophizing Scale (PCS), a 13-
item questionnaire which evaluates pain-related rumination, helplessness and magnification 
[39]; (2) Spielberger's State-Trait Anxiety Inventory (STAI), which allows a distinction to be made 
between anxiety as a trait of personality or an emotional response to a situation [40]; (3) the 
Beck Depression Inventory (BDI-II), a 21-item questionnaire assessing symptoms of depression 
[41]; (4) the Pain Anxiety Symptoms Scale (PASS-20), evaluating fear of pain during intercourse 
[42]; and (5) the Patient's Global Impression of Change (PGIC), a patient-reported measure 
selected to evaluate perceived reduction in pain using a 7-point scale that ranges from ‘very 
much improved’ to ‘very much worse’ [43]. 
Alterations in PFM morphology have been demonstrated in women with PVD using 
transperineal four-dimensional (4D) ultrasound [12]. Using this validated and reliable 
methodology [44], [45] and [46], several parameters are evaluated at rest and during PFM 
contraction: levator hiatus area and diameter, bladder neck positioning and displacement as 
well as levator plate and anorectal angles. An intravaginal dynamometric speculum, developed 
by our team to evaluate PFM function [47], [48], [49] and [50], is also used in this trial. This 
instrument has been widely assessed for its psychometric properties including its reliability, 
validity and responsiveness [49], [50], [51], [52], [53] and [54]. PFM dysfunctions identified in 
women with PVD, namely heightened passive forces, stiffness and lower strength, speed of 
contraction and endurance [11], are evaluated in this trial. 
2.7. Multimodal physiotherapy treatment 
The physiotherapy treatment consists of ten 60-minute weekly sessions with a physiotherapist 
specialized in gynecological pain. With a view to investigating an intervention that reflects 
clinical practice, different treatment modalities were selected according to the usual practice of 
physiotherapists in North America [14]. The educational component of our intervention includes 
explanations about the PVD pathophysiology, the involvement of PFM, healthy vulvo–vaginal 
and sexual behaviors, chronic pain and factors influencing pain intensity, relaxation techniques, 
sexual function and recovery of non-painful sexual activities. Approximately 20–25 min are 
dedicated to manual techniques (stretching, myofascial release techniques, pressure and 
massage) to increase flexibility, release muscle tensions and trigger points in the PFMs. 
Depending on the patient's pain referral pattern, these techniques are also applied to the 
obturator internus, piriformis, gluteus, adductors and abdominal muscles. The techniques are 
adapted to each patient and evolve throughout the treatment sessions (e.g. from one to two 
fingers, more pressure or stretching applied). A 20 min period of biofeedback (Evadri, ®Hollister, 
Biomation, Canada) is applied using a small intravaginal probe to promote relaxation, control 
and strength, speed of contraction and endurance. The daily home exercise program 
incorporates deep breathing exercises, PFM contraction and control, stretching using dilatator 
as well as massage and tissue mobilization of the vulvar vestibule. Additionally, partners are 
convened to attend a session to discuss the pathophysiology of PVD, sexual activities and how 
to perform PFM stretching exercises. 
2.8. Lidocaine treatment 
For the lidocaine treatment, participants are asked to apply the 5% lidocaine ointment (50 mg/g, 
Lidocan®, Odan Lab, 35 g) to the vestibule every night as described by Zolnoun et al. [26]. After 
gently cleaning and drying the vulvar area, the participants are asked to apply a small blob of 
ointment (size of a marble) on the affected region (i.e. the vestibule) without rubbing. The same 
amount is then applied on a small cotton gauze pad which is positioned at the entry of the 
vagina. The gauze should remain in continuous contact with the vestibule overnight 
(approximately 8 h). The participant is asked to wear cotton underwear to help maintain the 
gauze in place. The treatment is repeated nightly for 10 weeks. The procedure is explained 
verbally by the research coordinator and an instruction sheet is given. 
2.9. Sample size 
The sample size was calculated based on the primary outcome — the intensity of pain during 
sexual intercourse evaluated with the NRS. Statistical power analysis examined the 
requirements to detect a clinically significant difference of 1.5 points between the two 
treatments with a two-sided significance level of 0.05, 80% power and 3.47 standard deviation 
[26]. Several studies of musculoskeletal conditions indicated that a reduction of 1.5 to 2.0 points 
in pain corresponds to a minimal clinically significant difference [56] and [57]. Moreover, the 
IMMPACT group recommends a 30% pain reduction as a threshold for clinical significance [34]; 
this would correspond to 1.8 points based on our previous study (baseline average pain of 6/10) 
[12]. In our studies investigating different treatments, a difference of 1.5 to 4.67 points was 
observed [18] and [24]. In the most conservative scenario, a sample of 170 participants (85 per 
group) would be necessary. To account for an expected drop-out rate of 20% after 6 months 
[18] and [28], 212 participants (170/0.80) need to be enrolled at baseline. This number provides 
sufficient power to meet the secondary objectives with power ranging from 84.4–99.9%. 
2.10. Statistical analysis plan 
Primary analysis: Analyses will be done based on the intention-to-treat principle. A multilevel 
model of change (growth model) will evaluate and compare the efficacy of the interventions by 
comparing values for the pain during intercourse at the different time-points and between 
groups [58]. This type of analysis takes into account the dependency between repeated 
measures without requiring identical intervals between time-points. It also allows the use of 
partial data from women who did not participate in all measurements. A piecewise linear-
growth model will be estimated since we anticipate that the changes between the evaluations 
pre- and post-treatments will be greater than with the 6-month follow-up. Moreover, the 
statistical model will be adjusted for the stratification variable (i.e. center). 
Secondary analysis: The same analysis will be used to compare the efficacy of the treatments on 
the secondary variables. The number of tests will be taken into account as the level of 
significance will be lowered using the Bonferroni correction. Exploratory analysis will also be 
used to determine the effect of adherence to the procedures on the treatment efficacy. 
3. Current status of the trial 
The first participant was enrolled on May 11, 2012. As shown in Fig. 1, a total of 537 women 
reporting pain at the entry of the vagina during intercourse were interested in participating and 
223 were found eligible at the telephone pre-screening process. Most common reasons for 
exclusion included having previously received physiotherapy or overnight lidocaine (21%), 
previous pregnancies (18%), pelvic and urogynecological pathologies (18%) and age (11%). As of 
August 30, 2015, the total sample size of 212 women had been recruited and randomized. 
Assessments are ongoing. It is expected that the study will be completed by December 2015 
with the last 6-month follow-up assessment. 
4. Discussion 
In the development and implementation of this first RCT investigating the efficacy of multimodal 
physiotherapy in women with PVD, several methodological issues were considered including the 
choice of intervention, the eligibility criteria, the duration of interventions, the participant 
adherence as well as other methods to control for potential bias. Moreover, when the study was 
launched, some challenges pertaining to low rate of recruitment and retention issues were 
encountered and some additional strategies were developed and implemented. 
4.1. Choice of interventions 
This trial compares physiotherapy, a promising intervention judged to be effective, with topical 
overnight lidocaine application, a frequently used first-line intervention [16] and [17]. 
Physiotherapy modalities, taken separately, have been shown to produce a significant reduction 
in pain during intercourse in women with PVD [18], [19] and [20]. However, their efficacy seems 
to be lower compared to a multimodal intervention [24] and [25]. Recommended in the 
treatment of chronic pain [59], a multimodal approach was selected to better represent 
treatment delivery in a clinical setting based on a survey of physiotherapists [14]. Despite 
excellent preliminary results [24] and [25], multimodal physiotherapy has never been studied in 
a randomized clinical trial with a large sample. With regard to the topical application of 
lidocaine, we also intended to reflect current clinical practice. Overnight application of lidocaine 
5% ointment was selected in our trial as this protocol has shown the highest efficacy so far [26] 
compared to daily application of lidocaine [27] and [28]. Application of lidocaine before 
intercourse has been described in clinical guidelines [16] and [17], but no data are yet available 
to support its efficacy. Furthermore, the design of this study does not entail comparison with an 
untreated or placebo control group. It was considered unethical to withhold women from 
treatment after previous studies had already reported effective treatments for PVD. Moreover, 
as patients participate actively in treatment, sham multimodal physiotherapy seemed unlikely to 
be credible for women. Our choice of study design is in line with current strategies used in non-
pharmaceutical trials whereas an active control or usual care comparison group is generally 
selected in order to prevent attrition bias due to an untreated study arm or non-credible 
placebo treatment [60]. Consequently, we opted for comparing multimodal physiotherapy to 
one of the most prescribed first-line treatments [15]. 
4.2. Eligibility criteria 
The targeted sample included women 18 to 45 years old. As shown by Harlow et al. [61], this 
age group is generalizable to the population of women with PVD given that it covers 87% of 
affected women. This is also consistent with our findings as only 11% of women interested in 
participating were excluded because of age. Inclusion of women close to the age of menopause 
might have introduced other pathologies related to dyspareunia such as vulvo–vaginal atrophy. 
Likewise, to avoid pain explained by childbirth-related lesions and to limit the confounding 
effect of pregnancy and delivery on PFM function, only nulliparous women were recruited. 
Women with moderate or severe pain during intercourse were included as they are 
representative of the PVD population [30], and their pain may also correspond to a typical level 
of severity at which many women will seek medical advice [6]. It will also prevent a floor effect 
and thus ensure that the intervention will have a measurable efficacy [62]. Moreover, a 6-month 
duration of symptoms was selected based on the DSM-V criteria for genito–pelvic 
pain/penetration disorders [63]. Having a stable sexual partner was one of the inclusion criteria. 
Although this may affect external validity, as not all women with PVD are currently engaged in a 
relationship, this criterion was necessary to investigate the study's primary outcome, i.e. change 
in pain intensity during intercourse. It has been suggested that oral contraceptives could 
influence vestibular sensitivity [64] and PVD development [9] but conflicting results were found 
in large epidemiological studies showing a non-significant impact [65] and [66]. It was therefore 
decided not to exclude women taking oral contraceptives but to verify this potential confounder 
and if relevant, incorporate it as a covariate in the statistical model. In sum, the eligibility criteria 
were chosen to best represent the reality of women with PVD while reducing the possibility of 
bias arising from a wrong diagnosis or confounding factors. 
4.3. Duration of interventions 
Patients were randomly assigned to one of the two 10-week treatment groups. The use of 
weekly physiotherapy treatments over a period of 10 weeks corresponds to current clinical 
practice [14]. In fact, to achieve the treatment's objective to target PFM function, an 8- to 12-
week training period is generally recommended [67]. As for lidocaine application, previous 
studies report treatment periods ranging from 7 weeks of an overnight application [26] to 12 
weeks of a 4–7 times daily application [27] and [28]. Since the overnight application was chosen 
in this study, a 10-week treatment is in accordance with previous studies and allows uniformity 
in the length of the two treatments. In order to limit the potential bias associated with the 
therapeutic relationship created with the physiotherapist, a weekly follow-up of the women in 
the lidocaine application group was included. This 15-minute follow-up phone call with the 
study coordinator allows the patient to ask questions during the treatments, address her 
worries and promote adherence to treatment. 
4.4. Outcome measures 
In this study, outcome measures were selected to evaluate every dimension of PVD and the 
potential impact of the treatment. The assessment tools used in this trial adhere to the 
recommendations of the IMMPACT consensus [34]. Accordingly, this protocol proposes a 
thorough evaluation of pain intensity and characteristics, physical functioning (sexual and 
muscle function in this study), emotional functioning and participant ratings of global 
improvement [34]. The primary outcome (i.e. pain intensity during intercourse) was selected 
based on its clinical relevance for women with PVD and, also, because the majority of current 
studies have also included this measure, which will facilitate inter-trial comparisons. All tools 
used in this study have good psychometric properties and have been used in our previous 
studies. 
4.5. Participant adherence to treatment 
First, at recruitment, a motivational interview is held with each participant and the barriers to 
following study procedures are discussed to promote adherence [68]. The participants are also 
asked to keep a diary to indicate if they do their exercises (physiotherapy group) or apply the 
ointment (lidocaine group) throughout the 10 weeks. Participants also indicate whether they 
feel pain related to the treatment and during intercourse. The diary is reviewed weekly by the 
physiotherapist (physiotherapy treatment) or study coordinator (lidocaine treatment) to discuss 
the patient's adherence to treatment and evolution of her pain. Moreover, several time periods 
for physiotherapy and telephone calls are proposed to the participant to accommodate her 
schedule. 
4.6. Methods to control bias 
Physiotherapists at both sites followed a standardized training and were given a written detailed 
evaluation form and a treatment protocol ensuring consistency of treatment and assessment 
procedure as well as reducing bias due to the evaluators. The assessment and treatment files 
are reviewed on a regular basis by the principal investigator in order to identify and address 
protocol deviations. In order to keep the blinding, treatment physiotherapists never conduct 
pre- and post-treatment or 6-month follow-up assessments. Lastly, women are also required to 
abstain from any other treatment during the study period (until the 6-month follow-up). To 
evaluate whether contamination of the intervention occurred, participants are asked at the 
post-treatment and 6-month assessments to declare if they received any other treatments than 
the one assigned to them during the study period. Participants are reminded of their 
appointments and receive a $40 compensation for each evaluation in order to enhance the 
likelihood of complete follow-up. 
4.7. Lessons learned 
Concerns about low recruitment rate were raised when the study was launched. Whereas initial 
recruitment sources mostly relied on posters and physician referrals, multiple recruitment 
strategies were thereafter deployed and intensified to increase the recruitment rate. The 
addition of newspaper ads, Facebook and web initiatives allowed us to increase the recruitment 
rate from 2 patients per month in the first year to more than 7 patients per month. Given the 
age group of the targeted sample, it is interesting to notice that Facebook and web initiatives 
represent 30% of the recruitment sources. The other recruitment source are distributed as 
follow: Posters in clinics, universities, professional schools, restaurants, gyms 32%, references by 
health professionals 17%, ads in local newspapers 11%, word to mouth 8% and public 
conference 2%. Furthermore, challenges in reaching the participants for their 6 month follow-up 
were encountered with the first participants completing the trial which was explained by the 
fact that a portion of participants moved to the cosmopolitan area for their education. Even 
though we excluded women unable to engage in the study until the last follow-up assessment, 
this population was more prone to moving during their studies and leaving the area when 
graduating. We have implemented several strategies to prevent attrition: 1) Collecting multiple 
contact information and reviewing these at each assessment (phone numbers, email); 2) adding 
a phone call at 3 months post-treatment to maintain contact with the participant and plan the 
follow-up assessment and 3) emphasizing the value of study completion and appreciation for 
patient's contribution at each assessment and at the 3 month post-treatment phone call. 
5. Conclusion 
This bi-center RCT addresses an important need to provide scientific evidence in support of PVD 
treatment option, a frequent yet neglected problem with significant psychosocial repercussions. 
It is the first RCT investigating the efficacy of a multimodal physiotherapy compared to another 
first-line treatment, overnight lidocaine application. Findings from this trial will provide 
important guidance for health professionals about the efficacy of two first-line treatments and 
will help to better direct their patients towards the best empirically validated treatment. 
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